Effect of empagliflozin/linagliptin on albuminuria and urinary liver-type free fatty acid binding protein in type 2 diabetic patients with chronic kidney disease: A randomized controlled trial
Phase 1
Completed
- Conditions
- T2DM and CKD patients with albuminuria
- Registration Number
- TCTR20210317005
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Age more than 18 years
T2DM
eGFR 30-59 ml/min/1.73m2
Stable glycemic treatment 3 months
No treatment adjusted with anti-HT within 1 month
Exclusion Criteria
Sepsis/ any organ infection
Current history of urinary and genital tract infection
History of diabetic ketoacidosis
Pregnancy
Pancreatic and active liver disease
Polycystic kidney disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change in urine L-FABP urinary L-FABP level at baseline, and at 12 weeks after treatment urinary L-FABP level by ELISA method
- Secondary Outcome Measures
Name Time Method urine albumin creatinine ratio at baseline before and at 12 weeks after treatment urine albumin creatinine ratio by standard laboratory of center